Fused bicyclic imidazoles

US8592591B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Swen Hölder · London, GB
• Armin Zülch · Schriesheim, DE
• Thomas Bar · Reichenau, DE
• Thomas Maier · Stockach, DE
• Astrid Zimmermann · Konstanz, DE
• Thomas Beckers · Konstanz, DE
• Volker Gekeler · Konstanz, DE
• Hemant Joshi · Navi Mumbai, IN
• Yogesh Munot · Providence, US
• Umesh Bhise · Ahmednagar, IN
• Sunil Chavan · Nashik, IN
• Sachin Shivatare · Pune, IN
• Sarvesh Patel · Jamkhed, IN
• Vikas Gore · Ahmednagar, IN

Key dates

• Filing date: Aug 14, 2008
• Grant date: Nov 26, 2013
• Expiry date: Dec 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I)a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.